Peripheral nerve pulsed radiofrequency for trigeminal neuralgia treatment: Is it an effective method?

OBJECTIVES: Trigeminal neuralgia is a paroxysmal and shock-like pain in the trigeminal nerve area. Various treatment options have been used for trigeminal neuralgia such as medical treatment, interventional procedures, and surgical operations. Pulsed radiofrequency (PRF) is a minimally invasive percutaneous technique which seems to be safer and easier to perform. This retrospective study aims to evaluate the analgesic effect, duration of efficacy, and side effects of PRF procedures in the peripheral branches of the trigeminal nerve. METHODS: The data of the patients with trigeminal neuralgia who were followed up in our hospital's algology clinic from 2016 to 2018 were reviewed retrospectively. Patients aged between 18 and 70 who did not respond to medical treatment or could not use medication due to side effects were treated with PRF procedure for peripheral branches of trigeminal nerve that was selected for this study. Demographic profile, clinical presentation, pain intensity, duration of efficacy, and complications were evaluated from their files. RESULTS: Twenty-one patients who underwent ultrasonography guided PRF procedures were included the study. Mean visual analog scale value of the patients was found to have decreased from 9.25±0.63 to 1.55±0.88 at the end of the 1st month (p<0.001). The painless period for the patients lasted up to 12 (9-21) months and no complications occurred. CONCLUSION: PRF procedure seems to be an effective and safe method in patients who respond to block of the peripheral branches of the trigeminal nerve.

IVIg-induced headache: prospective study of a large cohort with neurological disorders.

BACKGROUND: Intravenous immune globulin (IVIg) is frequently used in some neurological diseases and is also the first-line therapy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. We aimed to evaluate the frequency and characteristics of headaches, which is one of the most common side effects of IVIg treatment. METHODS: Patients who received IVIg treatment for neurological diseases were prospectively enrolled in 23 centers. Firstly, the characteristics of patients with and without IVIg-induced headaches were analyzed statistically. Then, patients with IVIg-induced headaches were classified into three subgroups determined by their history: no primary headache, tension-type headache (TTH), and migraine. RESULTS: A total of 464 patients (214 women) and 1548 IVIg infusions were enrolled between January and August 2022. The frequency of IVIg-related headaches was 27.37% (127/464). A binary logistic regression analysis performed with significant clinical features disclosed that female sex and fatigue as a side effect were statistically more common in the IVIg-induced headache group. IVIg-related headache duration was long and affected daily living activities more in patients with migraine compared to no primary headache and TTH groups (p = 0.01, respectively). CONCLUSION: Headache is more likely to occur in female patients receiving IVIg and those who develop fatigue as a side effect during the infusion. Clinicians' awareness of IVIg-related headache characteristics, especially in patients with migraine, may increase treatment compliance.